Bayesian Capital Management’s Emergent Biosolutions EBS Stock Holding History

Bayesian Capital Management’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-38,901	Closed	-$372K	–	703
2024 Q4	$372K	Buy	+38,901	New	+$357K	0.05%	440
2021 Q1	–	Sell	-5,700	Closed	-$511K	–	576
2020 Q4	$511K	Buy	5,700 +1,681	+42%	+$154K	0.13%	212
2020 Q3	$415K	Buy	+4,019	New	+$433K	0.1%	270
2019 Q2	–	Sell	-4,012	Closed	-$203K	–	549
2019 Q1	$203K	Buy	+4,012	New	+$237K	0.04%	470
2018 Q1	–	Sell	-10,084	Closed	-$469K	–	638
2017 Q4	$469K	Buy	+10,084	New	+$424K	0.1%	331

Other funds holding EBS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

OHA

Oak Hill Advisors New York $878M AUM 106.46% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bayesian Capital Management's EBS Position: Q1 2025 in Review

Bayesian Capital Management sold out of Emergent Biosolutions (EBS) in Q1 2025, closing a stake of 38,901 shares — an estimated $372K sold.

Bayesian Capital Management first reported a position in EBS in Q4 2017 and held it in 5 quarters. The position peaked at $511K in Q4 2020. 160 funds tracked by Wall St. Rank hold EBS as of Q1 2025.

Bayesian Capital Management reported no remaining Emergent Biosolutions position as of Q1 2025 after selling out during the quarter.
Bayesian Capital Management sold 38,901 Emergent Biosolutions shares in Q1 2025, an estimated $372K.
Bayesian Capital Management first reported a position in Emergent Biosolutions in Q4 2017 and held it in 5 quarters.
Bayesian Capital Management's Emergent Biosolutions position peaked at $511K in Q4 2020.
160 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2025.

Based on Bayesian Capital Management's 13F filing for Q1 2025, filed 15 May 2025.